<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_Aberdeen_Scotland"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu noprint"><UL><LI class="selected"><A href="/Team:Aberdeen_Scotland">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:Aberdeen_Scotland&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:Aberdeen_Scotland&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:Aberdeen_Scotland&amp;action=history">History               </A></LI><LI style="color:white;cursor:default">teams</LI></UL></DIV><DIV class="right-menu noprint" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:Aberdeen_Scotland" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls" class="noprint"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:Aberdeen Scotland</H1><DIV id="bodyContent"><H3 id="siteSub" class="noprint">From 2014.igem.org</H3><P><TITLE>Team:Aberdeen Scotland - 2014.ogem.org</TITLE></P><DIV id="wrapper"><DIV id="header"><DIV id="navbar"><UL class="navbar"><LI><A class="Act" href="https://2014.igem.org/Team:Aberdeen_Scotland">Home</A></LI><LI><A href="https://2014.igem.org/Team:Aberdeen_Scotland/Team">Team</A></LI><LI><A href="https://2014.igem.org/Team:Aberdeen_Scotland/Project">Project</A></LI><LI><A href="https://2014.igem.org/Team:Aberdeen_Scotland/Parts">Parts</A></LI><LI><A href="https://2014.igem.org/Team:Aberdeen_Scotland/Modeling">Modelling</A></LI><LI><A href="https://2014.igem.org/Team:Aberdeen_Scotland/Notebook">Notebook</A></LI><LI><A href="https://2014.igem.org/Team:Aberdeen_Scotland/Safety">Safety</A></LI><LI><A href="https://2014.igem.org/Team:Aberdeen_Scotland/Attributions">Attributions</A></LI><LI><A href="https://2014.igem.org/Team:Aberdeen_Scotland/Ethics">Ethics &amp; Outreach</A></LI></UL></DIV></DIV><DIV id="pcontent"><DIV id="sidebar"><UL class="sidebar"><LI class="curr"><A class="curr" href="https://2014.igem.org/Team:Aberdeen_Scotland">Overview</A></LI></UL></DIV><DIV id="container"><DIV class="t_overview"><H1>Aberdeen iGEM Team 2014</H1><H3>Wake up to the Sleeping Sickness</H3></DIV><DIV class="main_content"><H3>Human African Trypanosomiasis – a Neglected Tropical Disease</H3><H4>The team was awarded a Gold medal and two special prizes:</H4><UL><UL><LI><B>Best Health &amp; Medicine Project</B> - Winner of Health &amp; Medicine Track</LI><LI><B>Best Innovation in Measurement</B> - Special Prize for unique assay design</LI></UL></UL><H4>*Ana and Konstantin receiving our two special prizes</H4><H3>Human African Trypanosomiasis – a Neglected Tropical Disease</H3><P>Trypanosoma brucei gambiense, the causative agent of Human African Trypanosomiasis (HAT) (commonly known as African Sleeping Sickness), infects 30,000 people
					worldwide, with 60 million at disease risk. Unrecognised, this disease is fatal, but accurate diagnosis, relying on detection of patient serum antibodies against two
					different trypanosomal antigens, Variable Surface Glycoprotein LiTat 1.3 and Variable Surface Glycoprotein LiTat 1.5, allows successful treatment.</P><H3>Our project and achievements</H3><P>We engineered autotransporters Antigen43 (Ag43) and Ice-Nucleation protein (INP) to successfully express surface epitopes in <I>E.coli</I>, that mimic the two different
					trypanosomal antigens. Therefore, we created standardised and user-friendly Ag43 and INP BioBricks ready for peptides of choice to be cloned in. Two <I>E.coli</I> strains
					were generated, each expressing a distinct surface epitope and either a quorum sensing sender or receiver module respectively. We delivered a proof-of-principle
					demonstration of our project, by showing that the quorum-based system is capable of detecting cell surface Ag43-FLAG ‘Receiver’ <I>E.coli</I> in an anti-FLAG bead pull-
					down. These ‘Receivers’ co-cultured with AHL-synthesising ‘Senders’ produced a strong –FLAG-tag dependent, AHL-inducible GFP response. This system if applied in a
					real life scenario could effectively diagnose a neglected tropical disease such as Trypanosomiasis, using patient serum-derived antibodies, with minimal facilities.
					</P><H3>The user-friendly, portable, inexpensive GFP detection device</H3><P>We constructed a cheap, Raspberry Pi computer-controlled fluorimeter suitable for developing countries, showing it could detect QS fluorescence output. The
					detection device costs around $100 and could replace heavy and expensive microscopes, to make the detection system affordable to remote populations in Africa.</P><H3>Novel applications</H3><P>This novel application to diagnose patient exposure to tropical pathogens integrates antigen display and quorum sensing to implement AND logic sensing. It
					facilitates cheap, simple diagnosis of neglected tropical diseases such as HAT. Future diagnosis kits can be constructed and modularized using the cheap and self-
					replenishing <I>E. coli</I> based detection system we created as a platform for displaying two different mimotopes. Mimotopes are shortened versions of real epitopes
					identified for a panel of diseases, all of which are currently stored in a universal database, available to everyone and known as MimoDB [http://immunet.cn/mimodb].
					Moreover, it was recently shown that upon heat-treatment of Ag43 autotransporter-foreign peptide complex at 60°C, a chimeric form of the expressed foreign protein
					can be isolated and remain fully active. The chimeric protein was then used to induce an immune response and to develop a novel vaccine for cancer therapy (Huang et
					al., 2014). Therefore, we suggest that further research can be done on Ag43-trypanosomal mimotope/ other mimotope complexes for a potential first vaccine for HAT/
					other diseases.</P><P><B>Reference:</B> Huang, F., Li, L., Liu, Q., Li, Y., Bai, R., Huang, Y., Zhao, H., Guo, J., Zhou, S., Wang, H. and others, (2014). Bacterial surface display of
					endoglin by antigen 43 induces antitumor effectiveness via bypassing immunotolerance and inhibition of angiogenesis. International Journal of Cancer, 134(8),
					pp.1981--1990.</P></DIV><DIV class="external"><P>You can find our official iGEM Registry Page <A href="https://igem.org/Team.cgi?year=2014&amp;team_name=Aberdeen_Scotland">here</A>.</P></DIV></DIV></DIV></DIV><DIV class="printfooter">
Retrieved from &quot;<A href="http://2014.igem.org/Team:Aberdeen_Scotland">http://2014.igem.org/Team:Aberdeen_Scotland</A>&quot;</DIV></DIV></DIV><DIV id="footer-box" class="noprint"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:Aberdeen_Scotland" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:Aberdeen_Scotland" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:Aberdeen_Scotland&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:Aberdeen_Scotland&amp;oldid=405121" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2014.igem.org:Privacy_policy" title="2014.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2014.igem.org:General_disclaimer" title="2014.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></BODY></HTML>